Sigma-1 Selective Drug Disappoints in Huntington's

(MedPage Today) -- BOSTON -- It's unclear whether pridopidine, an investigational drug targeting the sigma-1 receptor, has a future in treating Huntington's disease (HD) after a phase III trial failed to deliver a clearly favorable verdict, according...
Source: MedPage Today Neurology - Category: Neurology Source Type: news